X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The patent describes that the Psilonex RX, entourage effect of both the specific psilocybin treatment period followed by a cannabidiol (CBD) cannabis derivative compound.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PsilonexRX
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Allied has under provisional patent the formulation and trademark for Psilonex™ RX. Along with this, Allied has access to a cohort of over 300 veterans, police, fire and ambulance personnel who are struggling with post trauma symptoms and are requesting Psilonex™ RX.
Lead Product(s): Psilocybine,Cordyceps,Lion\'s mane
Therapeutic Area: Psychiatry/Psychology Product Name: Psilonex RX
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: HAVN Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 30, 2021
Details:
The patent application covers Allied’s proprietary products, ALID-10 and ALID-11, as well as other novel cannabis derived compounds designed for superior pharmaceutical properties for treatment of PTSD and other mental disorders.
Lead Product(s): ALID-10
Therapeutic Area: Psychiatry/Psychology Product Name: ALID-10
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
